Hologic is a medical technology company focused on women's health. It makes and sells diagnostic tests, breast imaging systems, and minimally invasive surgical devices used to screen for and treat conditions including cervical cancer, breast cancer, STIs, vaginitis, uterine fibroids, and abnormal uterine bleeding. Hologic sells primarily to hospitals, clinical labs, and physician practices through a direct sales force in the U.S. and a mix of direct and distributor channels internationally. The business runs across four segments: Diagnostics (~44% of revenue), Breast Health (~36%), GYN Surgical (~17%), and Skeletal Health (~3%). The Diagnostics segment is built around the Panther instrument platform, where Hologic places instruments in labs under multi-year contracts and earns recurring per-test revenue as customers run proprietary assays — a reagent rental model that creates sticky, high-margin revenue streams. Breast Health combines capital equipment sales (3D mammography gantries) with service contracts on roughly 15,000 installed gantries worldwide, with service now representing over 45% of segment revenue, plus single-use interventional breast products. GYN Surgical is a disposables-driven business, where per-procedure devices like MyoSure and NovaSure generate recurring revenue tied to procedure volumes. Hologic's growth strategy centers on expanding the Panther assay menu, refreshing the mammography installed base with a next-generation gantry (Envision, expected late 2026), growing international surgical sales, and tuck-in M&A targeting assets that fit existing commercial channels.